Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates. The stock has gained 434.64% over the last 5 years ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current ... U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a note on Friday said prescriptions ...

Mounjaro and Zepbound are Eli Lilly's ... 42.5 billion yen -- down from the initial forecast of 56.5 billion yen. The company cited delays in the sales launch in the U.S. for the newly protracted ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current market consensus ... closely-watched weekly U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a ...